MC10, Shirley Ryan AbilityLab partner on neurodegenerative disease
MC10, a company delivering wearable sensor systems for personalized health insights, and the Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago), a nationally recognized rehabilitation research hospital, announced their collaboration around novel neurodegenerative and motion related disability therapy development.
The Shirley Ryan AbilityLab will execute clinical research studies using MC10’s BioStampRC product, a wearable sensor system designed to seamlessly capture physiological data from across the body. MC10 and the hospital have partnered with the goal of determining how the BioStampRC System can be employed in clinical and home environments to advance the rehabilitation process.
“MC10’s technology has the potential to reshape rehabilitation. We look forward to developing new therapies and solutions with BioStampRC sensors, furthering our goal of improving treatment and recovery, and of advancing human ability,” stated David Zembower, Ph.D., Executive Director of Innovation and Clinical Research at the Shirley Ryan AbilityLab.
The research partnership will focus on identifying unmet clinical and therapeutic needs in the physical medicine and rehabilitation field. Initial target areas will include injuries that result in motion/biomechanics-related disabilities, especially stroke, traumatic brain injury, incomplete spinal cord injury, and various neurodegenerative diseases.
“MC10 is dedicated to improving healthcare with digital solutions. By collaborating with the Shirley Ryan AbilityLab, an institution committed to driving breakthroughs in human ability, we’re positioning our technology to make a real, positive impact in human health,” commented Scott Pomerantz, Chief Executive Officer of MC10.
The Shirley Ryan AbilityLab and MC10 plan for multiple publications and conference proceedings to share outcomes from their clinical study collaboration.